Irinotecan pharmacogenetics: Influence of pharmacodynamic genes

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1788-1796

  Hoskins, Janelle M ^a   Marcuello, Eugenio ^b   Altes, Albert ^c   Marsh, Sharon ^a   Maxwell, Taylor ^a   Van Booven, Derek J ^a   Paré, Laia ^b   Culverhouse, Robert ^a   McLeod, Howard L ^a,d   Baiget, Montserrat ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Hospital Esperit Sant   (Spain)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE DIVISION 45 LIKE PROTEIN; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR FACTOR KAPPA B P50 SUBUNIT; PHOSPHODIESTERASE; RALTITREXED; TYROSYL DNA PHOSPHODIESTERASE 1; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AFRICA; AGED; ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; PHARMACOGENETICS; PHYLOGENY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 41549141441     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1472     Document Type: Article

References (43)

1. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-59.
2. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-11.
3. Marsh S, Yu J, Hoskins JM. Colorectal cancer pharmacogenomics. Curr Colorectal Cancer Rep 2006;2: 217-24.
4. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006;20:163-75.
5. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004;5:835-43.
6. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002;62:608-17.
7. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-9.
8. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
9. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-5.
10. Pommier Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anti-Canc Agents 2004;4:429-34.
11. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22:7296-304.
12. Reid RJ, Fiorani P, Sugawara M, Bjornsti MA. CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc Natl Acad Sci U S A 1999;96:11440-5.
13. Malanga M, Althaus FR. Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 2004;279:5244-8.
14. Barthelmes HU, Habermeyer M, Christensen MO, et al. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J Biol Chem 2004;279:55618-25.
15. Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002;62: 459-65.
16. Cusack JC, Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
17. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678-82.
18. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999;8:367-70.
19. Freimuth RR, Xiao M, Marsh S, et al. Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet 2005;14:3595-603.
20. Freimuth RR, Stormo GD, McLeod HL. PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat 2005;25: 110-7.
21. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 1998;8:1229-31.
22. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45.
23. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005;14:1810-8.
24. Hu Z, Ma H, Lu D, et al. A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics 2005;15:457-63.
25. Lockett KL, Hall MC, Xu J, et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004;64:6344-8.
26. Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005;65:722-6.
27. Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004;64:4378-84.
28. Marsh S, King CR, Garsa AA, McLeod HL. Pyrose-quencing of clinically relevant polymorphisms. Methods Mol Biol 2005;311:97-114.
29. Clement M, Posada D, Crandall KA. TCS: a computer program to estimate gene genealogies. Mol Ecol 2000;9:1657-9.
30. Templeton AR, Crandall KA, Sing CF. A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping and DNA sequence data. III. Cladogram estimation. Genetics 1992;132:619-33.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
32. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999;2:307-18.
33. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 2003;31:5526-33.
34. Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol 2002;22: 2556-63.
35. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-71.
36. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 2000;275:40974-80.
37. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001;21:3075-9.
38. Suh KW, Kim JH, Kim DY, Kim YB, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006;13:1379-85.
39. Fan J, Otterlei M, Wong HK, Tomkinson AE, Wilson DM III. XRCC1 co-localizes and physically interacts with PCNA. Nucleic Acids Res 2004;32:2193-201.
40. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6.
41. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
42. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226-36.
43. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006;106:1007-16.